The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
DiaMedica said it plans to launch the trial later in 2026
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
The company announced positive topline data from the Phase II ZUPREME-1 trial
The system also introduces Imaging Scanner Interface 2 (ISI2) capability, enabling direct communication between injector and scanner to improve exam coordination and operational efficiency
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
Subscribe To Our Newsletter & Stay Updated
